Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1949 2
1950 1
1951 1
1952 1
1956 2
1965 1
1968 9
1969 3
1971 3
1972 2
1973 9
1974 7
1975 11
1976 14
1977 11
1978 16
1979 5
1980 9
1981 22
1982 17
1983 16
1984 26
1985 15
1986 23
1987 22
1988 14
1989 13
1990 17
1991 22
1992 17
1993 21
1994 24
1995 21
1996 14
1997 14
1998 22
1999 26
2000 25
2001 27
2002 30
2003 38
2004 63
2005 54
2006 63
2007 78
2008 106
2009 121
2010 139
2011 162
2012 176
2013 202
2014 196
2015 249
2016 252
2017 258
2018 285
2019 306
2020 330
2021 412
2022 372
2023 343
2024 162

Text availability

Article attribute

Article type

Publication date

Search Results

4,340 results

Results by year

Filters applied: . Clear all
Page 1
Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial.
Ray-Coquard I, Leary A, Pignata S, Cropet C, González-Martín A, Marth C, Nagao S, Vergote I, Colombo N, Mäenpää J, Selle F, Sehouli J, Lorusso D, Guerra Alia EM, Bogner G, Yoshida H, Lefeuvre-Plesse C, Buderath P, Mosconi AM, Lortholary A, Burges A, Medioni J, El-Balat A, Rodrigues M, Park-Simon TW, Dubot C, Denschlag D, You B, Pujade-Lauraine E, Harter P; PAOLA-1/ENGOT-ov25 investigators. Ray-Coquard I, et al. Among authors: rodrigues m. Ann Oncol. 2023 Aug;34(8):681-692. doi: 10.1016/j.annonc.2023.05.005. Epub 2023 May 19. Ann Oncol. 2023. PMID: 37211045 Free article. Clinical Trial.
Tapinarof for the treatment of psoriasis.
Nogueira S, Rodrigues MA, Vender R, Torres T. Nogueira S, et al. Among authors: rodrigues ma. Dermatol Ther. 2022 Dec;35(12):e15931. doi: 10.1111/dth.15931. Epub 2022 Oct 21. Dermatol Ther. 2022. PMID: 36226669 Free PMC article. Review.
[SFC in 2024].
Rodrigues M. Rodrigues M. Bull Cancer. 2024 Jan;111(1):3-4. doi: 10.1016/j.bulcan.2023.12.006. Bull Cancer. 2024. PMID: 38245331 French. No abstract available.
Wireless, closed-loop, smart bandage with integrated sensors and stimulators for advanced wound care and accelerated healing.
Jiang Y, Trotsyuk AA, Niu S, Henn D, Chen K, Shih CC, Larson MR, Mermin-Bunnell AM, Mittal S, Lai JC, Saberi A, Beard E, Jing S, Zhong D, Steele SR, Sun K, Jain T, Zhao E, Neimeth CR, Viana WG, Tang J, Sivaraj D, Padmanabhan J, Rodrigues M, Perrault DP, Chattopadhyay A, Maan ZN, Leeolou MC, Bonham CA, Kwon SH, Kussie HC, Fischer KS, Gurusankar G, Liang K, Zhang K, Nag R, Snyder MP, Januszyk M, Gurtner GC, Bao Z. Jiang Y, et al. Among authors: rodrigues m. Nat Biotechnol. 2023 May;41(5):652-662. doi: 10.1038/s41587-022-01528-3. Epub 2022 Nov 24. Nat Biotechnol. 2023. PMID: 36424488
[The 2023 SFC year].
Rodrigues M. Rodrigues M. Bull Cancer. 2023 Jan;110(1):3-4. doi: 10.1016/j.bulcan.2022.12.004. Bull Cancer. 2023. PMID: 36631216 French. No abstract available.
Nivolumab plus chemoradiotherapy in locally-advanced cervical cancer: the NICOL phase 1 trial.
Rodrigues M, Vanoni G, Loap P, Dubot C, Timperi E, Minsat M, Bazire L, Durdux C, Fourchotte V, Laas E, Pouget N, Castel-Ajgal Z, Marret G, Lesage L, Meseure D, Vincent-Salomon A, Lecompte L, Servant N, Vacher S, Bieche I, Malhaire C, Huchet V, Champion L, Kamal M, Amigorena S, Lantz O, Chevrier M, Romano E. Rodrigues M, et al. Nat Commun. 2023 Jun 22;14(1):3698. doi: 10.1038/s41467-023-39383-8. Nat Commun. 2023. PMID: 37349318 Free PMC article. Clinical Trial.
The woman's hand.
Neder Filho AT, Costa ACD, Barros RSM, Nakachima LR, Souza SCA, Rodrigues MP, Oliveira RK, Gama SAMD. Neder Filho AT, et al. Among authors: rodrigues mp. Rev Assoc Med Bras (1992). 2023 Aug 4;69(suppl 1):e2023S108. doi: 10.1590/1806-9282.2023S108. eCollection 2023. Rev Assoc Med Bras (1992). 2023. PMID: 37556627 Free PMC article. No abstract available.
Concurrent Olaparib and Radiotherapy in Patients With Triple-Negative Breast Cancer: The Phase 1 Olaparib and Radiation Therapy for Triple-Negative Breast Cancer Trial.
Loap P, Loirat D, Berger F, Rodrigues M, Bazire L, Pierga JY, Vincent-Salomon A, Laki F, Boudali L, Raizonville L, Mosseri V, Jochem A, Eeckhoutte A, Diallo M, Stern MH, Fourquet A, Kirova Y. Loap P, et al. Among authors: rodrigues m. JAMA Oncol. 2022 Dec 1;8(12):1802-1808. doi: 10.1001/jamaoncol.2022.5074. JAMA Oncol. 2022. PMID: 36301572 Free PMC article. Clinical Trial.
Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysis.
Labidi-Galy SI, Rodrigues M, Sandoval JL, Kurtz JE, Heitz F, Mosconi AM, Romero I, Denison U, Nagao S, Vergote I, Parma G, Nøttrup TJ, Rouleau E, Garnier G, El-Balat A, Zamagni C, Martín-Lorente C, Pujade-Lauraine E, Fiévet A, Ray-Coquard IL. Labidi-Galy SI, et al. Among authors: rodrigues m. Ann Oncol. 2023 Feb;34(2):152-162. doi: 10.1016/j.annonc.2022.11.003. Epub 2022 Nov 28. Ann Oncol. 2023. PMID: 36564284 Free article.
4,340 results